Bevacizumab

Bevacizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetVEGF-A
Clinical data
Pronunciation/ˌbɛvəˈsɪzjʊmæb/[1]
Trade namesAvastin, others
Other namesbevacizumab gamma
Biosimilarsbevacizumab-adcd,[2] bevacizumab-awwb,[3] bevacizumab-bvzr,[4] bevacizumab-maly,[5] bevacizumab-nwgd,[6] bevacizumab-tnjn,[7] Abevmy,[8] Alymsys,[9][5] Avzivi,[7][10][11] Aybintio,[12] Bambevi,[13] Bevacip,[14] Bevaciptin,[14] Equidacent,[15] Jobevne[6] Mvasi,[16] Onbevzi,[17][18] Oyavas,[19] Vegzelma,[2][20][21] Zirabev[22]
AHFS/Drugs.comMonograph
MedlinePlusa607001
License data
Pregnancy
category
Routes of
administration		Intravenous, intravitreal
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability100% (IV only)
Elimination half-life20 days (range: 11–50 days)
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC6638H10160N1720O2108S44
Molar mass149198.87 g·mol−1
 NY (what is this?)  (verify)

Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease.[32][30] For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma.[33] In many of these diseases it is used as a first-line therapy.[32][30] For age-related macular degeneration it is given by injection into the eye (intravitreal).[32]

Common side effects when used for cancer include nose bleeds, headache, high blood pressure, and rash.[32] Other severe side effects include gastrointestinal perforation, bleeding, allergic reactions, blood clots, and an increased risk of infection.[32] When used for eye disease side effects can include vision loss and retinal detachment.[32] Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor.[32] It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A), in other words anti–VEGF therapy.[32]

Bevacizumab was approved for medical use in the United States in 2004.[34][32] It is on the World Health Organization's List of Essential Medicines.[35]

  1. ^ "Bevacizumab Injection: MedlinePlus Drug Information". NLM.nih.gov. 28 February 2014. Archived from the original on 25 March 2014.
  2. ^ a b c Cite error: The named reference Vegzelma FDA label was invoked but never defined (see the help page).
  3. ^ a b "Mvasi- bevacizumab-awwb injection, solution". DailyMed. 25 June 2019. Archived from the original on 27 July 2020. Retrieved 18 March 2020.
  4. ^ a b "Zirabev- bevacizumab-bvzr injection, solution". DailyMed. 27 January 2020. Archived from the original on 27 July 2020. Retrieved 18 March 2020.
  5. ^ a b c "Alymsys- bevacizumab-maly injection, solution". DailyMed. 13 April 2022. Archived from the original on 10 June 2022. Retrieved 20 April 2022.
  6. ^ a b Cite error: The named reference Jobevne FDA label was invoked but never defined (see the help page).
  7. ^ a b Cite error: The named reference Avzivi FDA label was invoked but never defined (see the help page).
  8. ^ a b Cite error: The named reference Abevmy EPAR was invoked but never defined (see the help page).
  9. ^ a b Cite error: The named reference Alymsys EPAR was invoked but never defined (see the help page).
  10. ^ Cite error: The named reference Avzivi EPAR was invoked but never defined (see the help page).
  11. ^ Cite error: The named reference Avzivi PI was invoked but never defined (see the help page).
  12. ^ a b Cite error: The named reference Aybintio EPAR was invoked but never defined (see the help page).
  13. ^ Cite error: The named reference Bambevi SBD was invoked but never defined (see the help page).
  14. ^ a b Cite error: The named reference AU biosimilar was invoked but never defined (see the help page).
  15. ^ a b Cite error: The named reference Equidacent EPAR was invoked but never defined (see the help page).
  16. ^ a b Cite error: The named reference Mvasi EPAR was invoked but never defined (see the help page).
  17. ^ a b Cite error: The named reference Onbevzi EPAR was invoked but never defined (see the help page).
  18. ^ a b "Onbevzi APMDS". Therapeutic Goods Administration (TGA). 6 February 2024. Archived from the original on 8 February 2024. Retrieved 7 March 2024.
  19. ^ a b Cite error: The named reference Oyavas EPAR was invoked but never defined (see the help page).
  20. ^ a b Cite error: The named reference Vegzelma EPAR was invoked but never defined (see the help page).
  21. ^ a b c "Vegzelma APMDS". Therapeutic Goods Administration (TGA). 18 September 2023. Archived from the original on 2 January 2024. Retrieved 7 March 2024.
  22. ^ a b Cite error: The named reference Zirabev EPAR was invoked but never defined (see the help page).
  23. ^ a b "Abevmy". Therapeutic Goods Administration (TGA). 15 September 2021. Archived from the original on 16 September 2021. Retrieved 17 September 2021.
  24. ^ "Bevacizumab Use During Pregnancy". Drugs.com. 30 July 2019. Archived from the original on 18 March 2020. Retrieved 18 March 2020.
  25. ^ "AusPAR: Bevacizumab". Therapeutic Goods Administration (TGA). 2 February 2022. Archived from the original on 31 May 2022. Retrieved 12 June 2022.
  26. ^ "Australian Public Assessment Report for Vegzelma" (PDF). Department of Health and Aged Care. 22 February 2024. Retrieved 18 August 2024.
  27. ^ "Summary Basis of Decision for Vegzelma". Health Canada. 2 May 2023. Archived from the original on 10 March 2024. Retrieved 18 June 2023.
  28. ^ "Vegzelma Product information". Health Canada. 3 January 2023. Archived from the original on 10 March 2024. Retrieved 18 June 2023.
  29. ^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
  30. ^ a b c "Avastin- bevacizumab injection, solution". DailyMed. 28 June 2019. Archived from the original on 27 July 2020. Retrieved 18 March 2020.
  31. ^ Cite error: The named reference Avastin EPAR was invoked but never defined (see the help page).
  32. ^ a b c d e f g h i "Bevacizumab". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
  33. ^ "Bevacizumab". National Cancer Institute. 5 October 2006. Archived from the original on 10 April 2020. Retrieved 22 December 2023.
  34. ^ "Drug Approval Package: Avastin (Bevacizum) NDA #125085". U.S. Food and Drug Administration (FDA). 8 March 2005. Archived from the original on 8 April 2021. Retrieved 29 December 2021.
  35. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.